Breast Cancer Study

The Cancer and Leukemia Group B (CALGB) 40101 trial compared four and six cycles of AC or single-agent paclitaxel in early breast cancer. The study was a 2X2 factorial design trial that also examined the effects of AC vs singleagent paclitaxel. ]]> CALGB 40101 enrolled over 3000 women with operable primary breast cancer and zero to three positive nodes between 2002 and 2008. Patients were randomly assigned to receive four cycles of AC, six cycles of AC, four cycles of paclitaxel, or six cycles of paclitaxel.]]>